Barclays Starts Impax Laboratories (IPXL) at Overweight

May 1, 2018 3:23 AM EDT Send to a Friend
Barclays initiates coverage on Impax Laboratories (NASDAQ: IPXL) with a Overweight rating and a price target of $27.00.Analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login